Estrogen bioactivation, genetic polymorphisms, and ovarian cancer

Thomas A. Sellers, Joellen M. Schildkraut, V. Shane Pankratz, Robert A. Vierkant, Zachary S. Fredericksen, Janet E Olson, Julie M Cunningham, William Taylor, Mark Liebow, Carol McPherson, Lynn C. Hartmann, Tuya Pal, Araba A. Adjei

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)2536-2543
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume14
Issue number11 I
DOIs
StatePublished - Nov 2005

Fingerprint

Genetic Polymorphisms
Catechol Estrogens
Ovarian Neoplasms
Estrogens
Genes
Cytochrome P-450 CYP1A1
DNA Adducts
Penetrance
Single Nucleotide Polymorphism
Case-Control Studies
Neoplasms
Logistic Models
Alleles
Genotype
Interviews
DNA
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Sellers, T. A., Schildkraut, J. M., Shane Pankratz, V., Vierkant, R. A., Fredericksen, Z. S., Olson, J. E., ... Adjei, A. A. (2005). Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 14(11 I), 2536-2543. https://doi.org/10.1158/1055-9965.EPI-05-0142

Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. / Sellers, Thomas A.; Schildkraut, Joellen M.; Shane Pankratz, V.; Vierkant, Robert A.; Fredericksen, Zachary S.; Olson, Janet E; Cunningham, Julie M; Taylor, William; Liebow, Mark; McPherson, Carol; Hartmann, Lynn C.; Pal, Tuya; Adjei, Araba A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 14, No. 11 I, 11.2005, p. 2536-2543.

Research output: Contribution to journalArticle

Sellers, TA, Schildkraut, JM, Shane Pankratz, V, Vierkant, RA, Fredericksen, ZS, Olson, JE, Cunningham, JM, Taylor, W, Liebow, M, McPherson, C, Hartmann, LC, Pal, T & Adjei, AA 2005, 'Estrogen bioactivation, genetic polymorphisms, and ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 11 I, pp. 2536-2543. https://doi.org/10.1158/1055-9965.EPI-05-0142
Sellers TA, Schildkraut JM, Shane Pankratz V, Vierkant RA, Fredericksen ZS, Olson JE et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiology Biomarkers and Prevention. 2005 Nov;14(11 I):2536-2543. https://doi.org/10.1158/1055-9965.EPI-05-0142
Sellers, Thomas A. ; Schildkraut, Joellen M. ; Shane Pankratz, V. ; Vierkant, Robert A. ; Fredericksen, Zachary S. ; Olson, Janet E ; Cunningham, Julie M ; Taylor, William ; Liebow, Mark ; McPherson, Carol ; Hartmann, Lynn C. ; Pal, Tuya ; Adjei, Araba A. / Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2005 ; Vol. 14, No. 11 I. pp. 2536-2543.
@article{17620d37d6c5488b85f7c826f5a6b7f1,
title = "Estrogen bioactivation, genetic polymorphisms, and ovarian cancer",
abstract = "Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.",
author = "Sellers, {Thomas A.} and Schildkraut, {Joellen M.} and {Shane Pankratz}, V. and Vierkant, {Robert A.} and Fredericksen, {Zachary S.} and Olson, {Janet E} and Cunningham, {Julie M} and William Taylor and Mark Liebow and Carol McPherson and Hartmann, {Lynn C.} and Tuya Pal and Adjei, {Araba A.}",
year = "2005",
month = "11",
doi = "10.1158/1055-9965.EPI-05-0142",
language = "English (US)",
volume = "14",
pages = "2536--2543",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11 I",

}

TY - JOUR

T1 - Estrogen bioactivation, genetic polymorphisms, and ovarian cancer

AU - Sellers, Thomas A.

AU - Schildkraut, Joellen M.

AU - Shane Pankratz, V.

AU - Vierkant, Robert A.

AU - Fredericksen, Zachary S.

AU - Olson, Janet E

AU - Cunningham, Julie M

AU - Taylor, William

AU - Liebow, Mark

AU - McPherson, Carol

AU - Hartmann, Lynn C.

AU - Pal, Tuya

AU - Adjei, Araba A.

PY - 2005/11

Y1 - 2005/11

N2 - Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.

AB - Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=28644450203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644450203&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0142

DO - 10.1158/1055-9965.EPI-05-0142

M3 - Article

C2 - 16284375

AN - SCOPUS:28644450203

VL - 14

SP - 2536

EP - 2543

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11 I

ER -